secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001213900-25-029629
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q1 prelim revenue $39.0M, raises H1 2025 net sales guidance to $62-$70M
--------------------------------------------------------------------------------

- Preliminary unaudited Q1 2025 net revenue of $39.0M; expects adjusted EBITDA above $22.5M.
- Raises H1 2025 net sales guidance for existing purchasing customers to $62M-$70M from prior range.
- Cash and short-term investments at March 31, 2025: approx. $77.5M.
- Phase 3 TPN study of DefenCath enrollment expected to begin late April; peak sales potential $150M-$200M.
- Forecasts patient utilization growth in H2 2025; unit shipments expected to exceed H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/0001213900-25-029629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/ea023738701-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-029629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer